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Abstract
Objective: The Guillain–Barre syndrome (GBS) is an acute, immune-mediated
disease of peripheral nerves. Plasmablasts and plasma cells play a central role in
GBS by producing neurotoxic antibodies. The standard treatment for GBS is
high-dose intravenous immunoglobulins (IVIg), however the working mecha-
nism is unknown and the response to treatment is highly variable. We aimed to
determine whether IVIg changes the frequency of B-cell subsets in patients with
GBS. Methods: Peripheral blood mononuclear cells were isolated from 67
patients with GBS before and/or 1, 2, 4, and 12 weeks after treatment with
high-dose IVIg. B-cell subset frequencies were determined by flow cytometry
and related to serum immunoglobulin levels. Immunoglobulin transcripts
before and after IVIg treatment were examined by next-generation sequencing.
Antiglycolipid antibodies were determined by ELISA. Results: Patients treated
with IVIg demonstrated a strong increase in plasmablasts, which peaked 1 week
after treatment. Flow cytometry identified a relative increase in IgG2 plas-
mablasts posttreatment. Within IGG sequences, dominant clones were identified
which were also IGG2 and had different immunoglobulin sequences compared
to pretreatment samples. High plasmablast frequencies after treatment corre-
lated with an increase in serum IgG and IgM, suggesting endogenous produc-
tion. Patients with a high number of plasmablasts started to improve earlier
(P = 0.015) and were treated with a higher dose of IVIg. Interpretation: High-
dose IVIg treatment alters the distribution of B-cell subsets in the peripheral
blood of GBS patients, suggesting de novo (oligo-)clonal B-cell activation. Very
high numbers of plasmablasts after IVIg therapy may be a potential biomarker
for fast clinical recovery.
Introduction
Intravenous immunoglobulin (IVIg) is the first-choice
treatment for the Guillain-Barre syndrome (GBS), which
is a B-cell and autoantibody-mediated disease of the
peripheral nerve. GBS is typically a monophasic postinfec-
tious disease, characterized by progressive weakness of the
limb and respiratory muscles. Other common symptoms
include sensory deficits and autonomic dysfunction. The
majority of GBS patients have serum antibodies directed
against gangliosides and other glycolipids enriched in the
peripheral nerve.1 These antibodies are able to activate
the complement cascade leading to nerve damage.2
Activation of B cells and maturation into plasmablasts
and plasma cells producing neurotoxic antibodies are
therefore key pathogenic events in GBS.
IVIg consists of pooled human IgG purified from thou-
sands of healthy individuals.3 Despite the demonstrated
efficacy of high-dose IVIg in GBS, about 25% of patients
still deteriorate during treatment, become paralytic, or
require artificial ventilation.4 It is not known why some
GBS patients improve following IVIg treatment, whereas
others deteriorate further. Although differences in pharma-
cokinetics may underlie the heterogeneous clinical response
to therapy,5 it is also possible that host-dependent differ-
ences in pharmacodynamic effects of IVIg play a role.
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Several mechanisms for the therapeutic efficacy of IVIg
have been described, including neutralization of autoanti-
bodies, inhibition of complement and cytokines as well as
interaction with (neonatal) Fc-receptors.6 In addition, there
are indications that IVIg treatment may result in selection
or a “reset” of the immunoglobulin repertoire.7,8 There is
evidence that IVIg may directly affect B cell function by
inducing B-cell proliferation and immunoglobulin synthesis
in vitro.9,10 Correspondingly, in vivo, IVIg was found to
induce an increase in the number of plasmablasts in the
peripheral blood of patients with GBS, myasthenia gravis,
and in chronic inflammatory demyelinating polyneuropa-
thy (CIDP).11 Such a response was not observed in GBS
patients treated with plasmapheresis. Importantly, the IVIg-
induced plasmacytosis was associated with improved clini-
cal outcome in GBS.11 Further understanding of whether
and how these plasmablasts contribute to clinical recovery
may provide critical clues for further optimizing treatment
for GBS and other antibody-mediated diseases.
Here we determined the relation between IVIg and B-cell
differentiation into plasmablasts, serum immunoglobulin
(Ig) levels, clinical outcome, and antiglycolipid antibody
levels in a large cohort of GBS patients treated with IVIg.
Furthermore, we used next-generation sequencing to ana-
lyze subclass and gene segment usage as well as amino acid
composition of the complementary determining region
(CDR)-3 of immunoglobulin sequences.
Our data indicate that IVIg treatment induced a de
novo B-cell response as evidenced by increased numbers
of plasmablasts, changes in BCR specificity and subclass
usage, and higher immunoglobulin levels. This response
may have clinical impact as patients with a very high
number of plasmablasts showed an earlier start of recov-
ery even though antiganglioside GM1 antibody titers were
higher at onset.
Methods
Ethics statement
Ethical approval to study GBS patients was granted by
the Erasmus MC Institutional Review Board (MEC-
2009-368). The use of biomaterials from healthy controls
was approved (MEC-2014-305, MEC-2016-202 and MEC-
2016-173). Written informed consent was obtained from
all participants.
Patients and controls
All patients with GBS participated in a trial, in which
patients with a poor prognosis, that is a score of ≥6
on the modified Erasmus GBS Outcome Score, assessed
1 week after the start of IVIg treatment (2 g/kg for
5 days) were randomized for a second course of IVIg
or placebo.12 Trial medication was started within 24 h
after randomization. Clinical data and blood samples
were collected from all patients, regardless of random-
ization. Inclusion criteria for patients were: fulfilling the
diagnostic criteria for GBS13 and first course of IVIg
treatment started within 2 weeks after onset of weak-
ness. Patients were excluded from participation if they
were younger than the age of 12, pregnant, breastfeed-
ing, known with IgA deficiency, or were unable to be
monitored for 6 months. Also, patients with preexisting
symptoms of a polyneuropathy or patients diagnosed
with a malignancy, AIDS or with a known allergic reac-
tion to blood products were excluded. Blood was col-
lected pretreatment, if possible, and 1, 2, 4, and
12 weeks after IVIg treatment. Physicians assessing clini-
cal outcome did not have access to data on B-cell sub-
sets and remained blinded to medication status at any
time during the study.
Healthy controls participated in the Rotterdam Biobank
for Inflammatory Neuropathies (ROBIN) and were
recruited among persons who were accompanying
patients at the Erasmus MC neurology outpatient clinic.
Exclusion criteria were: existence of immune-mediated
diseases, recent infection, use of anti-inflammatory drugs,
and malignancy (not in remission).
Quantification of peripheral blood B-cell
subsets using flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated
from 67 GBS patients and 14 healthy controls (HC) using
CPT tubes and directly stained with CD19-PE/Cy7,
CD27-APC, CD38-PerCP, IgD-PE, and IgM-FITC to
determine the relative distribution of na€ıve, memory, and
natural effector B cells, as well as plasmablasts within the
total B-cell population. Cells were measured on a BD
Canto flow cytometer.
Simultaneously, a 100-lL whole-blood sample from
EDTA blood (GBS patients: n = 45, HC: n = 14) was
stained to quantify the total number of B cells per mL
peripheral blood using TruCount tubes (BD Bio-
sciences). Cells were stained for 20 min on ice using
CD16-FITC, CD56-PE, CD19-PE/Cy7, CD45-BV510,
and CD3-AF700. Next, erythrocytes were lysed using
1 mL 0.155 mol/L NH4Cl, 10 mmol/L KHCO3, and
0.1 mmol/L Na2 EDTA.2H2O for 15 min on ice and
the remaining cells were measured on a BD-LSR II
flow cytometer.
The total number of B cells was calculated using the
ratio between CD45+ CD19+ cells and the number of
beads measured in the same tube. Next, the absolute
numbers of B-cell subsets were calculated using the
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relative frequencies within the total CD19+ B-cell popula-
tion as described above.
Antiganglioside antibody ELISA
Serum obtained from 67 patients was isolated and stored
at 80°C and later thawed to measure IgG and IgM anti-
ganglioside antibodies; GM1, GM2, GD1a, GD1b, and
GQ1b. As previously described,14 with minor modifica-
tions, half-area plates were coated with 150 pmol of the
glycolipid per well and incubated with 1:100 diluted
serum. Sera were tested in duplicate, the ΔOD490 nm cal-
culated by subtracting the OD490 nm of uncoated wells
from that of coated wells, and titrated if positive (accord-
ing to previously defined cutoff values), starting at a
1:100 dilution with twofold dilutions. The antibody titer
was defined as the lowest dilution with a ΔOD490 nm
above the cutoff value.
Quantification of immunoglobulin levels
Serum total IgA, IgG, and IgM levels were determined by
routine immunoturbidimetry using Tina-quant assays and
a Cobas c 501 analyzer (Roche Diagnostics). Samples
from patients obtained after randomization for a second
course of IVIg or placebo were not tested.
Analysis of Ig-heavy and Ig-light chain
expression in B-cell subsets
Cryoprotected PBMC from 20 GBS patients and 20
healthy controls were thawed and plated in V-bottom
plates at 106 cells/well (IgH staining) or 5 9 105 cells/
well (IgL staining). Cells were subsequently washed in
PBS and incubated with Live/Dead Aqua reagent
(Molecular Probes, ThermoFisher Scientific) at room
temperature for 30 min and washed. The antibody mix
consisted of: IgD-bio, CD27-BV421, CD38-APC/Cy7,
and either CD19-BV786 (IgH staining) or CD19-PE/Cy7
(IgL staining). Cells were incubated with the antibody
mix for 30 min on ice. Next, cells were stained with
streptavidin-PerCP. To perform intracellular Ig staining,
cells were washed and fixed with 2% paraformaldehyde
for 15 min on ice and subsequently washed and perme-
abilized using 0.5% saponin for 15 min on ice. Intracel-
lular staining was then performed for 60 min on ice
with the antibody mix diluted in 0.5% saponin. For the
IgH staining, the mix consisted of IgG2-AF488, IgG1-PE,
IgA-PE/Vio770, IgG3-AF647, and IgM-AF700. For the
IgL staining, lambda-FITC and kappa-PE were used.
Lastly, cells were washed with 0.5% saponin and
subsequently with PBS/2% FCS and measured on a BD-
LSR II flow cytometer.
B-cell repertoire sequencing using
next-generation sequencing
RNA was extracted from frozen PBMC from three GBS
patients before, and 1 week after IVIg treatment and from
5 age- and gender- matched healthy controls (GenElute
Mammalian total RNA miniprep, Sigma Aldrich). After
reverse transcription using Superscript II reverse tran-
scriptase (Invitrogen) and random hexamer primers, IGH
transcripts were amplified using VH1-6 framework region
(FR1; BIOMED-2) forward and IGHA, IGHM, and IGHG
reverse primers combined with unique multiplex identi-
fier sequences per constant chain.15 After amplification,
DNA was purified using gel electrophoresis and Ampure
DNA purification. sscDNA was subsequently amplified
using EmPCR and sequenced using the 454 GS with the
Lib-A V2 kit as previously described.15
B-cell repertoire data analysis
Samples were demultiplexed based on their multiplex
identified sequence and 10nt were trimmed from both
ends to remove the primer sequences using IGGalaxy.16
FASTA files were subsequently uploaded into IMGT and
further analyzed using the IGGalaxy tool ARGalaxy.17
Using ARGalaxy and excel, data on IgH subclass, CDR3
length, and CDR3 composition were obtained, filtering
for productive sequences only. Data were further analyzed
in two different ways to correct for biased amplification
during the processing of the mRNA, being; (1) analysis
based on all productive acquired sequences and (2) based
on productive unique sequences where a unique sequence
is identified as combination of a specific CDR3 nucleotide
sequence, constant region, and V gene.
Statistical analysis
Data on B-cell subsets were expressed as absolute num-
bers or percentages and analyzed using Graphpad Prism
software (version 5). Time points were compared using
Kruskal–Wallis tests followed by Dunn’s multiple com-
parisons tests unless indicated otherwise. All correlation
analyses were performed according to Spearman. Differ-
ences in clinical outcome were evaluated using Kaplan–
Meier survival curves and log-rank tests with SPSS soft-
ware (version 24). Cutoff points were analyzed using Cut-
off Finder.18 A P-value of <0.05 was considered
statistically significant.
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Results
Peripheral blood plasmablasts are increased
in GBS patients treated with IVIg
In order to investigate B-cell subsets and their dynamics
during treatment with IVIg, we performed flow cytometry
on whole blood and on freshly isolated PBMC from GBS
patients and healthy controls (see Fig. 1A for the gating
strategy of B-cell subsets).
The number of peripheral blood B cells was not signifi-
cantly different between healthy controls and GBS
patients before treatment (Fig. 1B). One week after treat-
ment, the number of B cells in GBS patients increased
from 217  112 cells/lL to 306  203 cells/lL, reaching
significance only when comparing the 1-week to the 4-
week time point (P < 0.05). No differences were found in
na€ıve, memory, and natural effector B cells between (pre-
treatment) patients and controls and treatment did not
affect the absolute numbers of these B-cell subsets
(Fig. 1C–E). The number of plasmablasts, defined as
CD19+/low CD38+ CD27+ cells, was elevated before treat-
ment in approximately one-third of the GBS patients
compared to controls (>15,000 cells/mL, which is the
mean plus three times the standard deviation of the con-
trols). One week after treatment with IVIg, a significant
increase was found in the number of plasmablasts (from
11.7  14.2 cells/lL pretreatment to 31.6  33.2 cells/lL
posttreatment; P < 0.05; Fig. 1F). There was a significant
correlation between the number of plasmablasts pretreat-
ment and after 1 week of treatment (rs = 0.69; P = 0.004;
n = 15). The number of plasmablasts decreased after
2 weeks, though not significantly, and further decreased 4
and 12 weeks after the start of IVIg treatment
(P < 0.001). The percent of plasmablasts ranged from
0.29% to 57.2% of total B cells (mean 12.0%), 1 week
after start of treatment (Fig. 1G). This was significantly
higher compared to samples collected pretreatment
(P < 0.01), and 4 and 12 weeks after treatment
(P < 0.001). Before treatment, the percent of plasmablasts
was elevated in one-third of the GBS patients (range
0.24–16.9%) compared to controls (range 0.35–3.76%),
but overall there was no significant difference.
The kinetics of the plasmablast appearance in the
peripheral blood suggests that the plasmablasts are
induced by IVIg. This is further supported by an
increased number and percent of plasmablasts 1 week
after IVIg treatment in a patient with acute-onset CIDP
(77,529 cells/mL; 28.3% of B cells) compared to 2 weeks
after treatment (7734 cells/mL; 4.8% of B cells). In addi-
tion, in a patient with a GBS-mimicking disease who was
treated with IVIg but later diagnosed with a spinal cord
infarction, plasmablasts increased from 2427 cells/mL
(2.2% of B cells) before IVIg to 19,755 cells/mL (18.6%
of B cells) 1 week after IVIg and then decreased again to
4098 (4.6% of B cells) 4 weeks after treatment (Fig. 1H),
similar to GBS (Fig. 1I).
In summary, a transient increase in both absolute and
relative numbers of plasmablasts is observed in patients
with GBS after treatment with IVIg.
Plasmablasts after IVIg treatment are
enriched for IgG2
The plasmablasts were further phenotyped by intracellular
staining for IgM, IgA, IgG1, IgG2, IgG3, and kappa and
lambda light chains (n = 20). All classes and subclasses
were produced by plasmablasts derived from patients
1 week after treatment (Fig. 2A). No differences were
observed in the frequency of IgM+, IgA+,and IgG+ plas-
mablasts between pretreatment and 1 week posttreatment
time points (determined as percent of total plasmablasts;
Fig. 2B–D). This implies that IgM+, IgA+, and IgG+ plas-
mablasts are all increased following IVIg treatment. How-
ever, within the IgG+ plasmablasts, we found a significant
increase in the percent of IgG2+ cells and a significant
decrease in the percent of IgG3+ cells 1 week posttreat-
ment compared to pretreatment samples (Fig. 2E–G). No
differences were found in the IgG subclass distribution of
memory B cells (data not shown). The kappa/lambda
ratio of plasmablasts analyzed from patients 1 week after
IVIg treatment was less skewed but not significantly
different compared to pretreatment plasmablasts (data
not shown).
We next determined the sequences of immunoglobulin
RNA transcripts from three patients before and after IVIg
treatment using 454 sequencing. IgG subclass analysis
showed that the percent of unique IgG2 transcripts was
significantly increased in patients 1 week after IVIg treat-
ment (Fig. 2H). Furthermore, after treatment with IVIg
there was less overlap of unique IGG2 sequences with
other classes and subclasses than before treatment
(Fig. 2I), which further suggests that IVIg is skewing
toward an IgG2 response.
Dominant B-cell clones are present in GBS
before and after treatment with IVIg
In order to identify possible B-cell clones present in
patients with GBS before and after treatment, we deter-
mined the percent of IgG sequences with the same CDR3
nucleotide length and identical V and D gene segment
usage in three patients and five controls. Two dominant
clones (>5% of all sequences) were found in one GBS
patient before treatment (45% and 5% of all sequences;
Fig. 3A) and in one out of five controls (Fig. 3B).
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Interestingly, patient 3 had elevated frequencies of VH4-
34 IgG sequences before treatment (15.3% of total IgG
sequences), which may be related to the preceding infec-
tion with Mycoplasma pneumoniae, which is known to
expand VH4-34 expressing B cells.19 After treatment,
dominant clones (6 in total) were observed in all GBS
patients, the largest clone of each patient contributing to
7.3%, 12.6%, and 6.0% of the total sequences. These
clones were predominantly of the IgG2 subclass. Analysis
of CDR3 amino acid sequences revealed highly homoge-
neous sequences both before and after treatment
(Fig. 3C). Analyzing the relationship between clones after
and before treatment, we found two dominant clones
after treatment that were already present before treatment.
Figure 1. The number and frequency of plasmablasts are increased in the peripheral blood of GBS patients treated with IVIg. B-cell subsets were
gated as indicated (A). Total B cells (CD19+ cells; (B), na€ıve B cells (CD19+ IgD+ CD27; (C), memory B cells (CD19+ IgD CD27+; (D), natural
effector B cells (CD19+ IgD+ CD27+; (E) and plasmablasts (CD19+/low CD27+ CD38+; (F) were quantified using flow cytometry. The percent
plasmablasts of total B cells is shown in G. An increase in the percent of plasmablasts was also found in an IVIg-treated patient with a spinal cord
infarction (H). A representative IVIg-treated GBS patients is shown in I. *P < 0.05; **P < 0.01; ***P < 0.001.
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Of these, one was present as dominant clone (also IGG2),
contributing to 5% of the sequences pretreatment
(Fig. 3D). For the other clone (both IGG1 and IGG2 after
treatment), only one sequence was found before treat-
ment (IGG1). For both clones exactly the same CDR3
amino acid sequence was observed before and after treat-
ment. Four other dominant clones after treatment were
not present before treatment, suggesting that IVIg pre-
dominantly induces a de novo B-cell response. For IgM
sequences, persisting dominant clones were observed in
two patients (Fig. S1).
These results indicate that dominant B-cell clones are
present in patients with GBS and that IVIg treatment
results in changes in immunoglobulin sequences suggest-
ing (oligo-)clonal activation of B cells.
Plasmablasts after IVIg treatment
contribute to immunoglobulin synthesis
Since the increase in plasmablasts may be caused by
apoptotic displaced plasmablasts due to FccRIIb crosslink-
ing,20 we investigated the functional capacity of plas-
mablasts to synthesize immunoglobulin in vivo.
Immunoglobulin levels were determined in sera from 60
GBS patients and correlated to the number and frequency
of plasmablasts, 1 week after treatment.
The serum IgM level and the percent of plasmablasts,
both measured 1 week after IVIg treatment, were not sig-
nificantly correlated (rs = 0.24; P = 0.07; Fig. 4A). How-
ever, a strong positive correlation was found between the
percent of plasmablasts and the delta IgM levels (increase
in IgM level posttreatment compared to pretreatment)
1 week after treatment (rs = 0.78; P < 0.0001; Fig. 4B)
and 2 weeks after treatment (rs = 0.74; P < 0.0001;
Fig. 4C). For IgG, a weak but significant correlation was
found with the percent of plasmablasts 1 week after treat-
ment (rs = 0.28; P = 0.03; Fig. 4D). The delta IgG 1 and
2 weeks after treatment correlated significantly with the
percent of plasmablasts (rs = 0.54; P = 0.002 and
rs = 0.44; P = 0.03, respectively; Fig. 4E and F). Regres-
sion analysis demonstrated that the delta IgG at 1 week,
but not 2 weeks, was also significantly influenced
(P = 0.014; b = 0.51) by the percent of plasmablasts
1 week after treatment when corrected for the IVIg dose.
The delta IgM at 1 week, but not at 2 weeks also showed
significant correlation with the absolute number of plas-
mablasts. For IgA, significant correlations were observed
between the percent of plasmablasts and the delta IgA
levels at 1 (rs = 0.41; P = 0.03) and 2 weeks (rs = 0.44;
P = 0.03) after treatment (data not shown).
Since IVIg does not contain IgM, the increase in IgM
must be caused by increased endogenous production.
Therefore, these data suggest that the observed plas-
mablasts are viable in vivo and contribute to
immunoglobulin synthesis.
Patients with high numbers of plasmablasts
after IVIg treatment start to improve earlier
Since the number of plasmablasts in the peripheral blood
of GBS patients 1 week after the start of IVIg therapy was
highly variable and not elevated in every patient, we
determined the relation between the plasmablasts and
clinical outcome.
No significant correlation was observed between the
number of plasmablasts 1 week after IVIg and the GBS
disability score at 4 weeks (P = 0.18, n = 43; Fig. 5A).
Next, using the absolute counts of plasmablasts in GBS
patients before the start of treatment as a cutoff point, we
discriminated patients with a high (>50,000 cells/mL) and
a low number (<50,000 cells/mL) of plasmablasts after
IVIg therapy. Demographic and clinical characteristics
were not significantly different between the two groups
(Table 1), with the exception of the IVIg dose which was
significantly higher in the group with high numbers of
plasmablasts (198  49 vs. 155  30 g IVIg; P < 0.05
Mann–Whitney U test). All patients who were random-
ized for a second course of IVIg or placebo (n = 8) had a
plasmablast count of <50,000/mL (mean 21880  13716
cells/mL). This was not significantly different from non-
randomized patients in the group of <50,000 plas-
mablasts/mL (P = 0.11).
Patients with a high absolute number of plasmablasts
at 1 week after IVIg treatment, acquired the ability to
walk unaided earlier than patients with a low absolute
number of plasmablasts (mean 4.0 weeks vs. 11.4 weeks),
Figure 2. IVIg-induced plasmablasts are enriched for IgG2. Intracellular staining of immunoglobulin classes and subclasses was performed on
cryo-preserved PBMC from GBS patients (n = 20) and healthy controls (n = 20). Plasmablasts (CD19+/low CD27+ CD38+) were gated and
expression of all classes and subclasses was observed (A; top panels pretreatment and lower panels posttreatment). No difference was found in
IgM (B), IgA (C), and IgG (D) positive plasmablasts before and 1 week after IVIg treatment. Quantification of IgG1 (E), IgG2 (F), and IgG3 (G)
subclasses demonstrated a significant shift in IgG subclass usage 1 week after IVIg treatment. Samples with few plasmablasts were excluded. IGG
transcripts analyzed by 454 sequencing also indicated a significant shift in unique IGG subclass sequences in GBS patients (n = 3) 1 week
posttreatment (H; two-way ANOVA followed by Bonferroni correction). The fraction of sequences found in IGG2 only, and not shared with other
(sub)classes was also increased after treatment (I; data represent means of three patients). *P < 0.05; **P < 0.01; ***P < 0.001.
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although this difference was not statistically significant
(P = 0.076, n = 42, logrank test, Fig. 5B). The time to
improvement was defined as number of weeks until a one-
point improvement on the GBS disability scale was
achieved. Overall, no significant correlation was found with
the number of plasmablasts 1 week after treatment
(P = 0.33, n = 43; Fig. 5C), however comparison of the
two subgroups indicated that patients with a high number
of plasmablasts started to improve earlier than patients
with a low number of plasmablasts (P = 0.015, n = 42, log-
rank test, Fig. 5D). This significant difference was also
observed when a range of cutoff values was applied
(36,000–68,000 plasmablasts/mL), demonstrating the
robustness of the cutoff value. After correction for age or
GBS disability score at entry, the time to improvement was
not significantly different between patients with high and
low numbers of plasmablasts (P = 0.07 and P = 0.085,
respectively; n = 41; Cox regression). The percent of plas-
mablasts 1 week after treatment was not related to clinical
outcome, that is the time to acquire the ability to walk
unaided, or the time to one-point improvement on the
GBS disability scale (data not shown).
In summary, patients with high plasmablast numbers
after IVIg treatment started to recover earlier and
regained the ability to walk earlier than patients with low
plasmablast numbers, however this effect was lost after
correction for other prognostic factors such as age and
GBS disability score at entry.
Figure 3. Dominant B-cell clones are present in GBS patients after treatment with IVIg. RNA was isolated from PBMC before and 1 week after
treatment with IVIg and immunoglobulin transcripts were sequenced. Potential clones were identified as the percent of (all) IGG sequences having
the same V and D region usage and the same CDR3 length. Within each patient, unique clones are represented by a different color (only clones
of >1%). Before treatment, a very dominant clone was identified in patient 1 (A). After treatment, the number of dominant clones (>5%,
indicated with asterisks) increased in all patients and dominant clones were more common than in healthy controls (n = 5; B). Analysis of the
CDR3 amino acid composition of the most prevalent clone of every patient before and after treatment identified common motifs (data shown as
frequency; C). Note that after treatment the most prevalent clones were of the IgG2 subclass. Comparison of the IgG clone frequency from
patient 1 before and after treatment revealed only little overlap between clones (D).
Figure 4. The percent of plasmablasts after 1 week of IVIg treatment correlates with the rise in serum IgM and IgG levels. Serum IgM (A–C) and
IgG (D–F) levels were determined before and after IVIg treatment and related to the percent of plasmablasts measured after 1 week of IVIg
treatment. Absolute IgM/G levels are shown in A and D, the delta IgM/G levels at 1 week in B and E, and the delta IgM/G level at 2 weeks are
indicated in C and F. Delta IgM/G levels were calculated compared to pretreatment levels, which were not available for all patients. Patients
randomized for a second course of IVIg or placebo were excluded from analysis in C and F.
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Higher anti-GM1 antibody titers in patients
with a high number of plasmablasts
Finally, the relation between plasmablasts and anti-
ganglioside antibodies was determined by measuring the
GM1 IgG titers pretreatment and at different time points
after treatment. GM1 was chosen because it is the most
frequent target for autoantibodies in GBS.
Sixteen patients with anti-GM1 IgG antibodies were
identified (24%). Patients with high numbers of plas-
mablasts posttreatment had higher titers of anti-GM1 IgG
antibodies pretreatment (P < 0.001; Fig. 6A). There was
no significant difference in the GM1 IgG titers at later
time points between patients with high or low frequencies
of plasmablasts. However, it was observed that anti-GM1
IgG titers remained high in patients with high numbers
of plasmablasts who already started to recover. Subclass
analysis of anti-GM1 antibodies (Fig. 6B–E) showed that
most patients had anti-GM1 antibodies of the IgG1 and/
or IgG3 subclass, as reported previously. IgG4 antibodies
were also identified in a subset of patients. In the major-
ity of the patients, no IgG2 antibodies reactive with GM1
developed following IVIg treatment. In only one patient,
with a high number of plasmablasts posttreatment, IgG2
antibodies against GM1 were detected. In this patient
anti-GM1 IgG1 and IgG3 did not increase after IVIg
treatment, suggesting that IVIg may promote an existing
IgG2 anti-GM1 antibody response.
In summary, patients with a high number of plas-
mablasts have higher titers of anti-GM1 antibodies at dis-
ease onset.
Discussion
GBS is a prototypic autoantibody-mediated disease which
is preferentially treated with IVIg. However, the effect of
IVIg on B cells in GBS in relation to immunoglobulin
levels, pathogenic antibodies, and clinical outcome is
poorly understood. Here we demonstrate that peripheral
blood plasmablasts are increased in GBS patients treated
with IVIg. The plasmablasts are enriched for IgG2 sub-
class and actively contribute to immunoglobulin secretion
in vivo. Molecular data indicate that IVIg induces a de
novo B-cell response, distinct from the pretreatment B-
cell response. High plasmablast numbers were associated
with an earlier start of recovery even though anti-GM1
antibody titers were higher at onset.
The increase in plasmablasts in GBS patients was tran-
sient, being the highest at 1 week after the start of IVIg
treatment. Concurrent treatment with high-dose methyl-
prednisolone did not affect plasmablast counts. The kinet-
ics are highly reminiscent of a vaccination response, in
which newly formed plasmablasts peak in the peripheral
blood on day 6–7 after vaccination.21,22 This suggests that
the increase in plasmablasts in GBS patients is a direct
response to IVIg treatment. Correspondingly, the total
Figure 5. Plasmablasts after IVIg treatment in relation to clinical outcome in GBS. The absolute number of plasmablasts in relation to the GBS
disability score determined 4 weeks after IVIg therapy (A) or the time to improve one grade on the GBS disability scale (C; y-axis in log2 scale;
n = 43). The time to reach independent walking (B) that is a GBS disability score of two, and the time to improvement of one grade on the GBS
disability scale (D) was compared in patients with high (≥50,000 cells/mL) and low absolute numbers (<50,000 cells/mL) using logrank testing
(n = 42).
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dose of the IVIg infusions was significantly higher in
patients who demonstrated a high number of plas-
mablasts 1 week after treatment. Moreover, an increase in
plasmablasts was not only found in patients with GBS but
also in a patient with acute-onset CIDP, and in a patient
with GBS-mimicking disease who was later diagnosed
with a spinal cord infarction both initially treated with
IVIg. These findings are in line with the results of Mori
et al.,11 showing that plasmablasts were also increased
1 week after IVIg treatment in other diseases and not in
GBS patients who underwent plasmapheresis or received
no treatment, indicating that the increase in plasmablasts
after 1 week of treatment is induced by IVIg rather than
GBS. Furthermore, our finding that IgG2+ plasmablasts
are increased after IVIg treatment does not correspond
with current concepts regarding GBS pathogenesis, since
the pathogenic antibody response in GBS is not associated
with the IgG2 subclass, but rather with IgG1 and IgG3.
Lastly, the timing of the blood sampling seems critical
because shortly after IVIg treatment (3 days), plas-
mablasts appear to be decreased in the peripheral blood
of most CIDP and multifocal motor neuropathy patients
treated with high-dose IVIg,23 however no data were pre-
sented from samples obtained 1 week after treatment.
Our findings correspond with results from in vitro
studies of de Grandmont et al. showing that IVIg
enhances the differentiation of CD40-activated B cells into
plasmablasts and immunoglobulin synthesis and secre-
tion.9 Importantly, in the latter study, only a small frac-
tion (<15%) of B cells differentiated in response to IVIg.
The antibodies were directed against diverse nonself- and
self-antigens, including F(ab)2 fragments but not Fc frag-
ments, suggesting that the antibodies are induced through
idiotype anti-idiotype interactions. Additionally, B cells
from patients with common variable immunodeficiency
secrete increased levels of IgM in vitro in the presence of
IVIg and anti-IgM as B-cell receptor crosslinker.10 In con-
trast, in the study by Heidt et al.,24 no effect of IVIg was
observed on B-cell proliferation or immunoglobulin pro-
duction. Strong stimulation of B cells with CpG and
cytokines in that study may possibly have rendered B cells
insensitive to IVIg. Another study has reported that IVIg
induces phosphorylation of extracellular signal-regulated
kinases (ERK)-1 and 2, especially in IgG+ cells.25 Our data
extend all these in vitro findings by demonstrating that
IVIg can also promote immunoglobulin synthesis in vivo,
as shown by the increase in IgM levels in patients with a
high percent (>20%) of plasmablasts. Since IVIg does not
contain IgM, the increase in IgM must be caused by
increased endogenous production of immunoglobulins.
This finding also indicates that the IVIg-induced plas-
mablasts are viable in vivo and do not represent displaced
apoptotic plasmablasts caused by FccRIIb crosslinking.20
The increase in IgG levels compared to baseline (i.e., the
delta IgG) at 1 and 2 weeks after IVIg treatment was also
significantly correlated with the percent of plasmablasts,
but the association was weaker than for IgM. This may be
due to the high levels of infused IgG, potentially masking
additional endogenous IgG production. IgG levels after
IVIg therapy are highly diverse in patients with GBS5 and
may be influenced by several complex mechanisms,
including redistribution to tissues, target-mediated clear-
ance, and FcRn-mediated recycling.26,27 The exact role of
endogenous IgG production by IVIg-responsive plas-
mablasts to serum IgG levels can only be investigated
using appropriate pharmacokinetic modeling correcting
for known confounding factors which was beyond the
scope of this study.
Recent in vivo studies in mice have demonstrated that
human IVIg, but not monoclonal humanized antibodies
used at the same dose, induce widespread T- and B-cell
activation.28 Interestingly, this response was only observed
when animals were coinjected with adjuvant. Additionally,
IVIg reduced the response to ovalbumin, which was also
Table 1. Demographics, laboratory, and clinical characteristics of
patients with high and low numbers of plasmablasts 1 week after IVIg
treatment.
Plasmablasts
after IVIg
<50,000
(n = 33)
Plasmablasts
after IVIg
≥50,000
(n = 11)
Demographic characteristics
Female, n (%) 10/33 (30) 5/11 (45)
Age, median (range) 60 (18–86) 50 (18–80)
Antecedent events
Diarrhea, n (%) 8/31 (26) 5/11 (45)
URTI, n (%) 11/31 (35) 2/11 (18)
Diarrhea and URTI, n (%) 3/31 (10) 2/11 (18)
Other, n (%) 2/31 (6) 0/11 (0)
None, n (%) 7/31 (23) 2/11 (18)
Characteristics of GBS
Days of weakness
before start of IVIg
therapy, median (range)
2 (0–12) 2 (1–10)
GBS disability score
at entry, median (range)
4 (1–4) 3 (1–4)
GBS disability score
at nadir, median (range)
4 (1–5) 4 (2–4)
Mechanical ventilation, n (%) 8/32 (25) 1/11 (9)
Antiganglioside
IgG antibodies, n (%)
12/33 (36) 5/11 (46)
Treatment
Total IVIg dose (g), mean (SD) 155 (30) 198 (49)*
Randomized for second
course of IVIg or placebo, n (%)
8/31 (26) 0/11 (0)
Methylprednisolone, n (%) 6/28 (21) 3/10 (30)
*P < 0.05, Mann–Whitney U test.
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present in the adjuvant.28 Here we found that IVIg-
induced plasmablasts were the highest in patients with an
ongoing humoral immune response before treatment (i.e.,
patients with a high number of plasmablasts). Likewise,
patients with higher number of plasmablasts after treat-
ment also had higher anti-GM1 antibody titers pretreat-
ment. This may suggest that an ongoing immune
response favors a microenvironment with increased levels
of survival factors for plasmablasts, such as myeloid cells
that secrete B-cell activating factor, a proliferation induc-
ing ligand, or interferon gamma-induced protein-10.29
IgG subclass analysis using flow cytometry demon-
strated that the IVIg-induced plasmablasts more fre-
quently produced IgG2 than plasmablasts before
treatment. The sequence data also indicated that after
treatment with IVIg the most dominant clones within
IgG were of the IgG2 subclass. IgG2 antibodies are typi-
cally, but not exclusively, produced against carbohydrate
antigens.30,31 These antigens, often repetitive in nature
(e.g., bacterial capsular polysaccharides), activate B cells
through extensive crosslinking of the B-cell receptor, and
do not require cognate help from T cells.32 It is possible
that high-dose IVIg induces similar crosslinking of the
BCR for example through idiotype anti-idiotype interac-
tions, as has been suggested from in vitro data.9 Alterna-
tively, glycosylation or glycation of IVIg preparations,33,34
may induce a preferential IgG2 response. Our data does
not clarify whether (sequential) class switching has
occurred or whether IgG2+ B cells are preferentially acti-
vated. However, IVIg did not induce IgG2 class switching
Figure 6. Patients with high plasmablast numbers after IVIg treatment have high GM1 IgG titers at onset. Pre- and posttreatment sera from GBS
patients positive for GM1 IgG antibodies (n = 12) were titrated by ELISA. Data is shown stratified according to low or high plasmablast count
assessed 1 week after IVIg treatment (A). A titer of <100 is considered negative. Two-way ANOVA followed by Bonferroni correction
(***P < 0.001). Subclass analysis of anti-GM1 antibodies (B–E) demonstrated that the majority of patients do not produce anti-GM1 antibodies of
the IgG2 subclass; only one patient is positive for anti-GM1 IgG2 1 week after treatment (C). The dotted line indicated the cutoff value
(DOD = 0.2).
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of anti-GM1 B cells, which were of the IgG1 and IgG3
subclass, as demonstrated previously.35 Our data support
these findings as our antiganglioside ELISA showed no
anti-GM1 IgG2 responses in almost all patients. More-
over, mouse studies have indicated that memory B cells
can be readily activated with particulate antigens in the
absence of T cells to differentiate into plasmablasts.36
The results of the next-generation sequencing demon-
strated the presence of a dominant B-cell clone before the
start of treatment in one out of three GBS patients. This
clone might represent a neuropathogenic clone since this
patient was positive for anti-GD1b IgG antibodies or may
be related to the preceding infection. Furthermore, we
noted dynamic changes in dominant clones before and
after treatment with IVIg. The Ig sequences expressed by
dominant clones after treatment were mostly absent or
present at very-low frequencies before treatment, suggest-
ing that IVIg induces a de novo response, which may be
a primary or a secondary response. The finding that dom-
inant clones were present after treatment, appear to be
increased, and have different sequences compared to the
dominant clones before treatment, suggests that IVIg
induces an (oligo-)clonal expansion of IgG2+ B cells. It is
still possible that this expansion occurs on top of a back-
ground of polyclonal activation, as flow cytometric analy-
sis demonstrated that all Ig classes were produced by
plasmablasts after IVIg therapy. However, the sequence
data do not allow discrimination between polyclonal acti-
vation of B cells and normal genetic diversity which is
present among resting cells. One other study investigated
the effect of IVIg on the immunoglobulin repertoire. In
patients under desensitization therapy prior to transplan-
tation, no changes were observed in the frequency of
unique sequences, mutation frequency, and the abun-
dance of switched sequences.37 The pretransplant patients
were treated with multiple, monthly courses of high-dose
IVIg, therefore the data suggest that IVIg does not change
the immunoglobulin repertoire in the long term but leads
only to a short wave of newly formed plasmablasts which
disappear over time.
Do the clear biological effects of IVIg on B cells in GBS
also translate into a beneficial effect on clinical recovery?
Although we found that patients with a high number of
plasmablasts after IVIg therapy started to improve signifi-
cantly earlier and had a tendency to acquire the ability to
walk earlier, no significant differences were found after
correction for confounding factors like age and GBS dis-
ability score at entry, which are known prognostic factors
for GBS. This is likely due to the relatively low number
of patients with high plasmablast counts (n = 11), result-
ing in insufficient power for analysis with confounding
factors. Further analysis is therefore required to determine
to what extent IVIg-induced plasmablasts can predict
rapid clinical recovery when age, disease severity, other
prognostic factors, and IVIg dose are taken into account.
Given that patients with high plasmablast numbers had
higher antibody titers to GM1 at onset (all ≥ 25600),
which are associated with poor recovery,38 it remains
remarkable that these patients started to recover earlier
than patients with low plasmablast numbers and lower
anti-GM1 IgG titers. This may be explained by differences
in fine specificity and pathogenicity of the antibodies. In
mice, it was recently demonstrated that if antiganglioside
antibodies are not able to bind gangliosides in tissue, they
remain elevated in the circulation because of a lack of tar-
get-mediated clearance.26 Whether the anti-GM1 antibod-
ies in patients with a high titer and a fast recovery are
pathogenic or nonpathogenic remains to be determined.
The improved clinical outcome of patients with high
numbers of plasmablasts may also be caused by a higher
dose of IVIg, since this was the only discriminative parame-
ter between the two groups. The higher dose of IVIg may
lead to improved neutralization of pathogenic antibodies,
or induce more efficient immunomodulation through
other mechanisms. That IVIg dosage affects clinical out-
come in GBS is demonstrated by a trial in which high dose
of IVIg (2.4 g/kg in 6 days) resulted in better clinical out-
come of GBS than a lower dose (1.2 g/kg in 3 days).39
In conclusion, our study indicates that IVIg can pro-
mote humoral responses in patients with GBS, as reflected
by an increase in peripheral blood plasmablasts, changes
in BCR specificity and subclass distribution, and endoge-
nous Ig production. A high number of plasmablasts after
IVIg treatment were associated with an earlier start of
recovery, despite higher titers of anti-GM1 antibodies,
and were related to a higher IVIg dose. Future studies
should address the reactivity of the plasmablasts and fur-
ther clarify the role of plasmablasts in the pharmacokinet-
ics of IVIg in relation to clinical outcome.
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Figure S1. Dominant IgM B-cell clones are present in
GBS patients before and after treatment with IVIg.
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